The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients

January 27, 2026 updated by: Sheng-Mou Hsiao, MD, Far Eastern Memorial Hospital
This study will elucidate the role of 3D transvaginal ultrasound in assessing (1) cervical vascularity and blood flow in patients with cervical cancer and cervical intraepithelial neoplasm, and (2) tumor vascularity and blood flow in patients with ovarian cancer.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Patients and methods:

Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, or the control will be invited to particilate in this study.Then, 3D power Doppler Ultrasound will be performed to capture (1) the cervical volume, vascularity and blood perfusion, and (2) ovarian tumor vascularity and blood perfusion. The sonographic data will be correlated to clinical and pathological data.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • New Taipei City, Taiwan, 220
        • Far Eastern Memorial Hospital
        • Contact:
    • Banqiao
      • New Taipei City, Banqiao, Taiwan, 22050
        • Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital,
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, and the disease-free control

Description

Inclusion Criteria:

  • Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions, and the correlation between hemoperfusion and prognosis":

    1. Adult women who have had a normal cervical smear within the past three years and have no other gynecological cancers (control group).
    2. Adult women with cervical cancer or precancerous lesions.

  • Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer":

    1. Adult women suspected of having ovarian cancer, fallopian tube cancer, or peritoneal cancer before surgery.

Exclusion Criteria:

  • Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions of the cervix, and the correlation between hemoperfusion and prognosis":

    1. Patients who cannot cooperate with vaginal 3D ultrasound scans.

  • Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer":

    1. Patients who cannot cooperate with vaginal or abdominal 3D ultrasound scans.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
cervical cancer
cervical cancer patients
Diagnostic test: Doppler ultrasound
3D doppler ultrasound to measure VI, FI, VFI.
cervical intraepithelial neoplasm
cervical intraepithelial neoplasm patients
Diagnostic test: Doppler ultrasound
3D doppler ultrasound to measure VI, FI, VFI.
control
Gynecological patients without cervical disease
Diagnostic test: Doppler ultrasound
3D doppler ultrasound to measure VI, FI, VFI.
ovarian cancer
ovarian cancer patients
Diagnostic test: Doppler ultrasound
3D doppler ultrasound to measure VI, FI, VFI.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vascularization-flow index
Time Frame: 3 years
  1. Compare the vascularization-flow index values between cervical cancer, cervical intraepithelial neoplasia and the control group.
  2. To assess whether vascularization-flow index is a predictor of progression-free survival in women with ovarian cancer
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vascularization index
Time Frame: 3 years
1. Compare the vascularization index values between cervical cancer, cervical intraepithelial neoplasia and the control group. 2. To assess whether vascularization index is a predictor of progression-free survival in women with ovarian cancer
3 years
Flow index
Time Frame: 3 years
1. Compare the flow index values between cervical cancer, cervical intraepithelial neoplasia and the control group. 2. To assess whether flow index is a predictor of progression-free survival in women with ovarian cancer
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Far Eastern Memorial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 19, 2026

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

January 13, 2026

First Submitted That Met QC Criteria

January 27, 2026

First Posted (Actual)

February 4, 2026

Study Record Updates

Last Update Posted (Actual)

February 4, 2026

Last Update Submitted That Met QC Criteria

January 27, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 114237-F

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe